<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03072446</url>
  </required_header>
  <id_info>
    <org_study_id>RHM RAD0041</org_study_id>
    <nct_id>NCT03072446</nct_id>
  </id_info>
  <brief_title>Uterine Fibroid Embolization (UFE) for Symptomatic Fibroids: Comparison of Gel-Bead to Commonly Used Embolic Agents.</brief_title>
  <official_title>Uterine Fibroid Embolization (UFE) for Symptomatic Fibroids: Comparison of Gel-Bead to Commonly Used Embolic Agents.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vascular Solutions LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Southampton NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-market study is to evaluate UFE agents for the treatment of&#xD;
      symptomatic uterine fibroids, using Gel-Bead compared to four other commonly used embolic&#xD;
      agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-center, prospective study will be conducted at one site in the United Kingdom. Up&#xD;
      to 30 subjects will be enrolled and treated with Gel-Bead. Prospectively. Enrolled Gel-Bead&#xD;
      subjects will be followed at 1-month and 3-months post-procedure.&#xD;
&#xD;
      Data from subjects treated with Gel-Bead will be compared to data from a previously&#xD;
      unpublished, but widely presented, 100-patient cohort study at the University Hospital&#xD;
      Southampton. This study evaluated 20 subjects in five different treatment groups for the&#xD;
      treatment of symptomatic uterine fibroids. The five treatment groups include gelatin foam&#xD;
      slurry, Embospheres, polyvinyl alcohol (PVA), Bead Block and Embozenes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of Fibroid Tissue Infarction at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>The primary endpoint is the degree of fibroid tissue infarction at 3 months post-procedure. Results for the total fibroid load and the dominant fibroid will be categorized as either 100% (Group A) â‰¥ 90-99% (Group B) or &lt;90% (Group C) infarcted. The degree of infarction will be visually estimated by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of adverse events over 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>The primary safety endpoint is to characterize adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in uterine and dominant fibroid volumes</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in uterine and dominant fibroid volumes between pre-procedure and Month 3 based on CE-MRI. The absolute dimensions of the uterus will be measured and the approximate uterine volumes will be calculated using the formula for a prolate ellipse (length X width X depth X 0.5233).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Uterine Fibroid</condition>
  <condition>Embolization</condition>
  <condition>Symptoms</condition>
  <arm_group>
    <arm_group_label>Gel-Beads arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will undergo embolization of symptomatic uterine fibroids with Gel-Beads embolic agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gel-Beads embolic material</intervention_name>
    <description>Patients will receive embolization of their uterine fibroids using Gel-Beads.</description>
    <arm_group_label>Gel-Beads arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female, age 18 years or older&#xD;
&#xD;
          2. Symptomatic uterine fibroid(s) requiring treatment per the investigators assessment&#xD;
&#xD;
          3. Negative serum pregnancy test at the Baseline visit and practicing effective&#xD;
             contraception during the study&#xD;
&#xD;
          4. Willing to provide written informed consent prior to initiation of study procedures&#xD;
&#xD;
          5. Willing to comply with the specified study assessments and follow-up requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to porcine products or intravascular contrast material&#xD;
&#xD;
          2. Vascular anatomy or blood flow precluding correct catheter placement or embolic&#xD;
             injection&#xD;
&#xD;
          3. Presence of collateral vessel pathways potentially endangering normal territories&#xD;
             during embolization&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Hacking</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southampton University Hospital NHS Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Fibroid</keyword>
  <keyword>Embolization</keyword>
  <keyword>symptoms</keyword>
  <keyword>Gel-Beads</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

